“Deucravacitinib Long-Term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program”. 2024. SKIN The Journal of Cutaneous Medicine 8 (6): s422. https://doi.org/10.25251/skin.8.supp.422.